2022 Revenues ($USD) : $47,697,382,199.00
2022 Revenues (foreign currencies) : CHF45,551,000,000
2022 R&D spend : $14,715,183,246.00
2022 Number of Employees : 46,793
Fiscal Year End : 12/31/22
Leader : CEO Teresa Graham

Roche reported a strong performance in 2022 in both its pharma and diagnostics divisions. Its pharma growth was driven by newer medicine introductions. The company's pipeline experienced some setbacks, but it made some progress, including the launches of Vabysmo and Lunsumio. The company met its sales guidance, and core earnings per share increased, leading the board to propose a dividend increase to CHF 9.50. Its pharmaceuticals division reported 2% growth (4% if adjusted for COVID sales). Roche's Pharma portfolio has diversified over the past five years, reducing the prominence of oncology while expanding into neuroscience, hemophilia A, and other areas. Roche expects to launch three new molecular entities in 2023: glofitamab, a collaboration with Sarepta in Duchenne muscular dystrophy, and crovalimab. Its sales outlook for 2023 indicates a low single-digit decline due to a reduction in COVID-related sales. However, Roche expects strong growth in its underlying Pharma business and continued momentum in its diagnostics base business. —BB